ERIN REED: Open Payments
NPI 1790863843 · MISSOULA, MT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$468 in 24 payments from 12 companies in 2025. Trend: 2023 $335 · 2024 $253 · 2025 $468
Food & beverage: $468
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| PFIZER INC. | 2 | $37 |
| Janssen Biotech, Inc. | 1 | $33 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| TerSera Therapeutics LLC | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
Products named: SKYRIZI, VIBERZI, ENTYVIO, TREMFYA, VOWST, Xermelo, IQIRVO, DUPIXENT.
Industry payments across MT — which companies pay providers there.
